INO · Inovio Pharmaceuticals, Inc. · Analyst Estimates
Substantial doubt about the company's ability to continue as a going concern.
“We do not currently have sufficient working capital to fund our planned operations for the next twelve months and substantial doubt exists as to our ability to continue as a going concern.”View the 10-Q filed Aug 12, 2026
Key customers — 100% of revenue (the years ended December 31, 2025 and 2024)
“During the years ended December 31, 2025 and 2024, we derived 100% of our revenue from ApolloBio.”
Analyst Estimates
Compare analyst forecasts for Inovio Pharmaceuticals, Inc. across metrics and forecast periods.
Estimates are grouped by forecast period, with low, average and high together. A dash means that statistic is not available.
Compiled consensus
These figures are a compiled consensus of analyst forecasts, not a survey the company published itself. Every figure is the statistic the source states; averages are means, never medians.
Captured 2026-10-22 19:33 UTC · Publication dates shown per estimate · 8 metric / period groups
FY ending 2026-12-31
| Metric | Low | Average | High | Analyst count | Average, 7 days ago | Average, 30 days ago | Average, 60 days ago | Average, 90 days ago | Estimates lowered, last 7 days | Estimates lowered, last 30 days | Estimates raised, last 7 days | Estimates raised, last 30 days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
EPS
USD
Publication date not stated |
-1.27
|
-1.00
|
-0.73
|
2
|
-0.73
|
-0.73
|
-0.73
|
-1.14
|
0
|
0
|
1
|
1
|
|
Revenue
USD
Publication date not stated |
0.00
|
666,670.00
|
2.00M
|
3
|
— | — | — | — | — | — | — | — |
FY ending 2027-12-31
| Metric | Low | Average | High | Analyst count | Average, 7 days ago | Average, 30 days ago | Average, 60 days ago | Average, 90 days ago | Estimates lowered, last 7 days | Estimates lowered, last 30 days | Estimates raised, last 7 days | Estimates raised, last 30 days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
EPS
USD
Publication date not stated |
-0.67
|
-0.44
|
-0.21
|
2
|
-0.44
|
-0.44
|
-0.44
|
-0.60
|
0
|
0
|
1
|
2
|
|
Revenue
USD
Publication date not stated |
13.30M
|
50.61M
|
80.00M
|
3
|
— | — | — | — | — | — | — | — |
Q ending 2026-09-30
| Metric | Low | Average | High | Analyst count | Average, 7 days ago | Average, 30 days ago | Average, 60 days ago | Average, 90 days ago | Estimates lowered, last 7 days | Estimates lowered, last 30 days | Estimates raised, last 7 days | Estimates raised, last 30 days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
EPS
USD
Publication date not stated |
-0.20
|
-0.20
|
-0.19
|
2
|
-0.20
|
-0.20
|
-0.20
|
-0.25
|
0
|
0
|
2
|
2
|
|
Revenue
USD
Publication date not stated |
0.00
|
0.00
|
0.00
|
3
|
— | — | — | — | — | — | — | — |
Q ending 2026-12-31
| Metric | Low | Average | High | Analyst count | Average, 7 days ago | Average, 30 days ago | Average, 60 days ago | Average, 90 days ago | Estimates lowered, last 7 days | Estimates lowered, last 30 days | Estimates raised, last 7 days | Estimates raised, last 30 days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
EPS
USD
Publication date not stated |
-0.18
|
-0.18
|
-0.18
|
2
|
-0.18
|
-0.18
|
-0.18
|
-0.26
|
0
|
0
|
2
|
2
|
|
Revenue
USD
Publication date not stated |
0.00
|
666,670.00
|
2.00M
|
3
|
— | — | — | — | — | — | — | — |